Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 33 | 1,183 | 33% |
| 2020 | 22 | 919 | 36% |
| 2021 | 21 | 930 | 39% |
| 2022 | 23 | 924 | 41% |
| 2023 | 27 | 1,036 | 43% |
| 2024 | 26 | 1,073 | 45% |
| 2025 from claims | – | 1,017 933–1,076 | 46% |
| 2026 forecast | – | 1,033 909–1,192 | 46% |
| 2027 forecast | – | 1,046 894–1,247 | 47% |
| 2028 forecast | – | 1,060 884–1,298 | 47% |
| 2029 forecast | – | 1,074 877–1,347 | 47% |
| 2030 forecast | – | 1,088 871–1,394 | 48% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 52% of the cases CMS names in New Jersey; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 23 | 1,666−3.1%/yr | −3.1%/yr | 1.2 | 0% | 1,760 in 2030+0.9%/yr |
| New York | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.8 | 0% | 1,510 in 20300%/yr |
| Massachusetts | 18 | 984−3.3%/yr | −3.3%/yr | 1.0 | 0% | 1,170 in 2030+2.9%/yr |
| Connecticut | 1 | 337−3.8%/yr | −3.8%/yr | 1.0 | 0% | 320 in 2030−1%/yr |
| New Hampshire | 4 | 267−3.3%/yr | −3.3%/yr | 1.2 | 0% | 360 in 2030+5.1%/yr |
| Maine | 0 | 161−5.5%/yr | −5.5%/yr | 1.0 | 0% | 670 in 2030+27%/yr |
| Rhode Island | 3 | 142+2.9%/yr | +2.9%/yr | 1.5 | 0% | 70 in 2030−11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.01.8× | 77% | 12,700 in 2030+6.4%/yr |
| Dialysis access | 58 | 7,071−13%/yr | −13%/yr | 7.01.3× | 70% | 7,590 in 2030+1.2%/yr |
| Superficial venous ablation | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.51.4× | 97% | 6,260 in 2030+4.1%/yr |
| Thrombectomy, IVC filters & venous stents | 25 | 1,782+1%/yr | +1%/yr | 1.71.3× | 28% | 1,690 in 2030−0.8%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 400−7.7%/yr | −7.7%/yr | 0.40.9× | 0% | 360 in 2030−1.6%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
Boston Scientific leads with 78% of company spending on these surgeons in 2025, −13 pts on 2024.
In 2025, 6 companies reported engagement with New Jersey’s surgeons worth $43K in consulting, speaking, meals and travel tied to these products, about $1,650 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.